Ash1l degraders and methods of treatment therewith
US-2024366774-A1 · Nov 7, 2024 · US
Aminoacyltransferases (2.3.2)
Aminoacyltransferases (2.3.2) · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C12Y203/02 |
| Official title | Aminoacyltransferases (2.3.2) |
| Display label | Aminoacyltransferases (2.3.2) |
| Total patents | 103 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is stable.
| Year | Patents |
|---|---|
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 8 |
| 2020 | 5 |
| 2021 | 17 |
| 2022 | 16 |
| 2023 | 21 |
| 2024 | 12 |
| 2025 | 14 |
| 2026 | 4 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Enhanced hyt-induced protein degradation using lipid nanoparticle delivery
US-2023414723-A1 · Dec 28, 2023 · US
Composition for regulating osteoclast differentiation, and use thereof
US-2023405092-A1 · Dec 21, 2023 · US
Ww-domain-activated extracellular vesicles
US-2023398202-A1 · Dec 14, 2023 · US
ASH1L degraders and methods of treatment therewith
US-11786602-B2 · Oct 17, 2023 · US
Methods and compositions for treating acute myeloid leukemia
US-2023265432-A1 · Aug 24, 2023 · US
Inhibitors of cbl autoinhibition and related methods
US-2023212239-A1 · Jul 6, 2023 · US
Methods of treating cancers
US-2023093238-A1 · Mar 23, 2023 · US
Modified UBE3A gene for a gene therapy approach for angelman syndrome
US-11534500-B2 · Dec 27, 2022 · US
Targeting rlim to modulate body weight and obesity
US-2022340903-A1 · Oct 27, 2022 · US
FcRn-targeted therapeutics for the treatment of antibody-mediated autoimmune and albumin-mediated disease
US-11471526-B2 · Oct 18, 2022 · US
Ube3a for the treatment of angelman syndrome
US-2022305098-A1 · Sep 29, 2022 · US
Ash1l inhibitors and methods of treatment therewith
US-2022288217-A1 · Sep 15, 2022 · US
Nucleic acid drug targeting murf1
US-2022267778-A1 · Aug 25, 2022 · US
Rational therapeutic targeting of oncogenic immune signaling states in myeloid malignancies via the ubiquitin conjugating enzyme ube2n
US-2022267753-A1 · Aug 25, 2022 · US
Methods of treating cancers
US-11413288-B2 · Aug 16, 2022 · US
Compositions for suppressing trim28 and uses thereof
US-2022135982-A1 · May 5, 2022 · US
Targeting egln1 in cancer
US-2022090083-A1 · Mar 24, 2022 · US
SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN dTAG SYSTEMS
US-2022089589-A1 · Mar 24, 2022 · US
Ash1l degraders and methods of treatment therewit
US-2022072142-A1 · Mar 10, 2022 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C12Y203/02?
- CPC C12Y203/02 is the Cooperative Patent Classification code for “Aminoacyltransferases (2.3.2).”
- How many patents are filed under CPC C12Y203/02 (Aminoacyltransferases (2.3.2))?
- Our database includes 103 publications tagged with this CPC code.
- Is patent activity under CPC C12Y203/02 growing?
- Publication counts under this code: 12 in 2024 vs 14 in 2025 (latest complete years).